Investment Analysts’ Weekly Ratings Changes for OrthoPediatrics (KIDS)

Several brokerages have updated their recommendations and price targets on shares of OrthoPediatrics (NASDAQ: KIDS) in the last few weeks:

• 8/5/2026 – OrthoPediatrics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/5/2026 – OrthoPediatrics was given a new $22.00 price target by Truist Financial Corporation.
• 8/5/2026 – OrthoPediatrics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $25.00 price target on the stock, up from $22.00.
• 8/5/2026 – OrthoPediatrics had its price target raised by Needham & Company LLC from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 7/17/2026 – OrthoPediatrics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – OrthoPediatrics had its price target raised by Truist Financial Corporation from $17.00 to $20.00. They now have a “hold” rating on the stock.
• 6/15/2026 – OrthoPediatrics had its “buy” rating reaffirmed by TD Cowen.

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.